Amundi MSCI Europe ESG Broad CTB UCITS ETF DR EUR C is a equity ETF from Amundi tracking the MSCI Europe ESG Broad CTB index through physical replication. Domiciled in Luxembourg and launched in 2018, the fund manages about 2.4 bn € and charges a TER of 0.12% — 12 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
Amundi MSCI Europe ESG Broad CTB UCITS ETF DR EUR C competes with 261 other products in the same class and region (Equity, Europe): it ranks 20th by fund size and 18th by ongoing cost, with a TER of 0.12% against a group median of 0.25%. It has been listed since 2018, 8 years of track record.
On a €10,000 investment the TER costs 12 € a year, against 25 € for the median product in the category.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 22.2% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in EUR. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
The fund is domiciled in Luxembourg, which determines the tax treatment of income received by the fund and the supervisory authority.
| ASML Holding N.V. | 5.6% |
| HSBC Holdings PLC | 2.4% |
| Novartis AG | 2.3% |
| Roche Holding AG | 2.2% |
| AstraZeneca PLC | 2.1% |
| Siemens Aktiengesellschaft | 1.6% |
| Allianz SE VNA O.N. | 1.5% |
| Banco Santander S.A. | 1.5% |
| TotalEnergies SE | 1.5% |
| ABB Ltd | 1.5% |
| Borsa Italiana | CEU | EUR |
| XETRA | CEUG | EUR |
| Francoforte | CEUG | EUR |
| Euronext Paris | CEU | EUR |
| SIX Swiss Exchange | CEU | EUR |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.